<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Iovance Biotherapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/iovance-biotherapeutics-inc</link>
<description>Latest news and press releases for Iovance Biotherapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 12:01:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/iovance-biotherapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835846878dffbe2df0fd177.webp</url>
<title>Iovance Biotherapeutics Inc</title>
<link>https://6ix.com/company/iovance-biotherapeutics-inc</link>
</image>
<item>
<title>Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026</title>
<link>https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-biotherapeutics-to-report-first-quarter-2026-financial-results-and-corporate-updates-on-thursday-may-7-2026</link>
<guid isPermaLink="true">https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-biotherapeutics-to-report-first-quarter-2026-financial-results-and-corporate-updates-on-thursday-may-7-2026</guid>
<pubDate>Mon, 27 Apr 2026 12:01:00 GMT</pubDate>
<description>SAN CARLOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Thursday, May 7, 2026 at 8:30 a.m. ET to report its first quarter 2026 financial results and corporate updates. To listen to the live or archived audio webcast, please register at ht</description>
</item>
<item>
<title>Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas</title>
<link>https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-announces-positive-results-from-the-first-clinical-trial-for-til-cell-therapy-in-soft-tissue-sarcomas</link>
<guid isPermaLink="true">https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-announces-positive-results-from-the-first-clinical-trial-for-til-cell-therapy-in-soft-tissue-sarcomas</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe</description>
</item>
<item>
<title>Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates</title>
<link>https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-biotherapeutics-highlights-strong-fourth-quarter-and-full-year-2025-results-business-achievements-and-corporate-updates</link>
<guid isPermaLink="true">https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-biotherapeutics-highlights-strong-fourth-quarter-and-full-year-2025-results-business-achievements-and-corporate-updates</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>~30% Quarterly Revenue Growth Driven by Amtagvi Demand Gross Margin Increased to 50% FY25 Revenue of $264M Achieved Annual Guidance U.S. FDA Fast Track</description>
</item>
<item>
<title>Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026</title>
<link>https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-biotherapeutics-report-fourth-quarter-210500437</link>
<guid isPermaLink="true">https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-biotherapeutics-report-fourth-quarter-210500437</guid>
<pubDate>Wed, 11 Feb 2026 21:05:00 GMT</pubDate>
<description>SAN CARLOS, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Tuesday, February 24, 2026 at 8:30 a.m. ET to report its fourth quarter and full year 2025 financial results and corporate updates. To listen to the live or archived audio webcast, pl</description>
</item>
<item>
<title>Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma</title>
<link>https://6ix.com/company/iovance-biotherapeutics-inc/news/best-class-real-world-data-221500623</link>
<guid isPermaLink="true">https://6ix.com/company/iovance-biotherapeutics-inc/news/best-class-real-world-data-221500623</guid>
<pubDate>Thu, 05 Feb 2026 22:15:00 GMT</pubDate>
<description>52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control RateSAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced data demonstrating a best-in-class profile for commercial Amtagvi® (lifileucel) with unprecedented response rat</description>
</item>
<item>
<title>Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-biotherapeutics-reports-inducement-grants-221500545</link>
<guid isPermaLink="true">https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-biotherapeutics-reports-inducement-grants-221500545</guid>
<pubDate>Fri, 16 Jan 2026 22:15:00 GMT</pubDate>
<description>SAN CARLOS, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on January 15, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 97,710 shares of Iovance’s common stock to 17 new, non-exe</description>
</item>
<item>
<title>Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results</title>
<link>https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-biotherapeutics-highlights-business-achievements-130000301</link>
<guid isPermaLink="true">https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-biotherapeutics-highlights-business-achievements-130000301</guid>
<pubDate>Thu, 06 Nov 2025 13:00:00 GMT</pubDate>
<description>Quarterly Revenue Growth of 13% to ~$68 Million Gross Margin Increased to 43% on Improved Execution and Operational Efficiency Best-in-Class Clinical Profile for Lifileucel in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) with Median Duration of Response Not Reached after 25+ Months Follow Up SAN CARLOS, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering nove</description>
</item>
<item>
<title>Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)</title>
<link>https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-biotherapeutics-reports-potential-best-120000464</link>
<guid isPermaLink="true">https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-biotherapeutics-reports-potential-best-120000464</guid>
<pubDate>Mon, 03 Nov 2025 12:00:00 GMT</pubDate>
<description>26% Objective Response Rate Median Duration of Response Not Reached after 25 Months Follow Up Lifileucel Launch in Previously Treated Advanced NSCLC Expected in Second Half of 2027 SAN CARLOS, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced interim data from its registr</description>
</item>
<item>
<title>Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025</title>
<link>https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-biotherapeutics-host-third-quarter-200500668</link>
<guid isPermaLink="true">https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-biotherapeutics-host-third-quarter-200500668</guid>
<pubDate>Thu, 23 Oct 2025 20:05:00 GMT</pubDate>
<description>SAN CARLOS, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its third quarter 2025 financial results and corporate updates before market on Thursday, November 6, 2025. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update</description>
</item>
<item>
<title>Iovance Biotherapeutics to Present at Upcoming Conferences</title>
<link>https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-biotherapeutics-present-upcoming-conferences-123000430</link>
<guid isPermaLink="true">https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-biotherapeutics-present-upcoming-conferences-123000430</guid>
<pubDate>Fri, 29 Aug 2025 12:30:00 GMT</pubDate>
<description>SAN CARLOS, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences: 2025 Wells Fargo Healthcare ConferenceFireside Chat: September 5, 2025 at 8:00 a.m. ETBoston, MA H.C. Wainwright 27th Annual Global Investment Conferen</description>
</item>
<item>
<title>Iovance’s Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma</title>
<link>https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-amtagvi-lifileucel-receives-health-201500698</link>
<guid isPermaLink="true">https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-amtagvi-lifileucel-receives-health-201500698</guid>
<pubDate>Mon, 18 Aug 2025 20:15:00 GMT</pubDate>
<description>First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced Health Canada has issued a Notice of Compliance with Condit</description>
</item>
<item>
<title>Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025</title>
<link>https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-biotherapeutics-reports-financial-results-200100771</link>
<guid isPermaLink="true">https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-biotherapeutics-reports-financial-results-200100771</guid>
<pubDate>Thu, 07 Aug 2025 20:01:00 GMT</pubDate>
<description>$60.0M in 2Q25 Total Product Revenue More than 100 Patients Treated with Amtagvi® in 2Q25 Strategic Restructuring Extends Cash Runway into 4Q26 FY25 Total Product Revenue Guidance of $250M-$300M Reiterated SAN CARLOS, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported secon</description>
</item>
<item>
<title>Iovance Biotherapeutics to Host Second Quarter and First Half 2025 Financial Results and Corporate Updates Webcast on Thursday, August 7, 2025</title>
<link>https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-biotherapeutics-host-second-quarter-200500566</link>
<guid isPermaLink="true">https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-biotherapeutics-host-second-quarter-200500566</guid>
<pubDate>Thu, 24 Jul 2025 20:05:00 GMT</pubDate>
<description>SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its second quarter and first half 2025 financial results and corporate updates on Thursday, August 7, 2025. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update</description>
</item>
<item>
<title>Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer</title>
<link>https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-biotherapeutics-appoints-corleen-roche-113000824</link>
<guid isPermaLink="true">https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-biotherapeutics-appoints-corleen-roche-113000824</guid>
<pubDate>Tue, 15 Jul 2025 11:30:00 GMT</pubDate>
<description>SAN CARLOS, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Corleen Roche as Chief Financial Officer (CFO), effective August 6th, 2025. “I am pleased to welcome Corleen to Iovance at such an important stage in our first commercial launch,” said Freder</description>
</item>
<item>
<title>Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma</title>
<link>https://6ix.com/company/iovance-biotherapeutics-inc/news/real-world-data-demonstrate-49-113000646</link>
<guid isPermaLink="true">https://6ix.com/company/iovance-biotherapeutics-inc/news/real-world-data-demonstrate-49-113000646</guid>
<pubDate>Mon, 14 Jul 2025 11:30:00 GMT</pubDate>
<description>61% Response Rate Observed in Third-Line or Earlier Patients SAN CARLOS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that a real-world, retrospective study demonstrates the benefit of commercial Amtagvi® (lifileucel) in real-world clinical settings for patients with</description>
</item>
<item>
<title>Iovance Biotherapeutics Appoints Marc R. Theoret, M.D. as Senior Vice President, Regulatory Strategy</title>
<link>https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-biotherapeutics-appoints-marc-r-200100741</link>
<guid isPermaLink="true">https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-biotherapeutics-appoints-marc-r-200100741</guid>
<pubDate>Thu, 10 Jul 2025 20:01:00 GMT</pubDate>
<description>SAN CARLOS, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Marc. R Theoret, M.D. to assume the newly created position of Senior Vice President, Regulatory Strategy, where he will focus on clinical regulatory strategy for Iovance’s pipeline. Effective</description>
</item>
<item>
<title>Iovance Biotherapeutics to Present at Upcoming Conference</title>
<link>https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-biotherapeutics-present-upcoming-conference-124500252</link>
<guid isPermaLink="true">https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-biotherapeutics-present-upcoming-conference-124500252</guid>
<pubDate>Tue, 10 Jun 2025 12:45:00 GMT</pubDate>
<description>SAN CARLOS, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conference: Goldman Sachs Global Healthcare ConferenceFireside Chat: June 11, 2025 at 1:20 p.m. ETMiami, FL The live and archived webcasts will be available at http</description>
</item>
<item>
<title>The Journal of Clinical Oncology Publishes Five-year Analysis of Amtagvi® (lifileucel) in Patients with Advanced Melanoma</title>
<link>https://6ix.com/company/iovance-biotherapeutics-inc/news/journal-clinical-oncology-publishes-five-132900328</link>
<guid isPermaLink="true">https://6ix.com/company/iovance-biotherapeutics-inc/news/journal-clinical-oncology-publishes-five-132900328</guid>
<pubDate>Mon, 02 Jun 2025 13:29:00 GMT</pubDate>
<description>One-time Amtagvi Treatment Continues to Show Deep, Durable Responses and Meaningful Survival One Third of Responses Remain Ongoing without Subsequent Treatment after Five Years Simultaneous Presentation at ASCO 2025 SAN CARLOS, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today anno</description>
</item>
<item>
<title>Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting</title>
<link>https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-announces-five-results-amtagvi-213100588</link>
<guid isPermaLink="true">https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-announces-five-results-amtagvi-213100588</guid>
<pubDate>Thu, 22 May 2025 21:31:00 GMT</pubDate>
<description>One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20% Five-year Follow Up is Unprecedented for Any Therapy in Patients with Advanced Melanoma Previously Treated with Immune Checkpoint Inhibitor SAN CARLOS, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patien</description>
</item>
<item>
<title>Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025</title>
<link>https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-biotherapeutics-reports-financial-results-200100237</link>
<guid isPermaLink="true">https://6ix.com/company/iovance-biotherapeutics-inc/news/iovance-biotherapeutics-reports-financial-results-200100237</guid>
<pubDate>Thu, 08 May 2025 20:01:00 GMT</pubDate>
<description>1Q25 Total Product Revenue of $49.3M FY25 Total Product Revenue Guidance Revised to $250M-$300M FY25 Operating Expenses Reduced and 2H26 Cash Runway Guidance Maintained 2025 Regulatory Approvals for Amtagvi® Expected in the UK, EU, and Canada On Track to Report Updated Clinical Data for Registrational Trialin Previously Treated Advanced NSCLC in 2H25 SAN CARLOS, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on in</description>
</item>
</channel>
</rss>